HBM Healthcare Investments AG
HBM Healthcare Investments AG (0QOC.L) Stock Overview
Explore HBM Healthcare Investments AG’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
1.1B
P/E Ratio
58.52
EPS (TTM)
$-11.22
ROE
0.01%
0QOC.L Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of HBM Healthcare Investments AG (0QOC.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 39.91, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $177.51.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 58.52 and a market capitalization of 1.1B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
HBM Healthcare Investments AG specializes in fund of funds and direct investments in middle market and mature companies. The fund prefers to invest in start up, early stage, mid stage, mid venture, late venture, and late stage private companies, unlisted emerging companies, small cap public companies, buyouts, growth capital, and private investment in public equities (PIPES). Within fund of funds, it invests in venture capital funds. It also seeks to finance spin-offs of product lines or departments from larger corporations and the expansion or restructuring of established companies, seed stages, venture capital, expansion capital stages, spin-offs, and buyouts. The fund prefers to invest in the private and public companies in the healthcare sector with a focus on human medicine, drugs, pharma , biopharma, biotechnology, diagnostics, medical technology, and related industries. It seeks to make initial investments in companies whose primary products are in clinical development or the immediately preceding stage. The fund typically invests globally with a focus on Asia Pacific, Asia, North America, and Europe. In case of public companies, it focuses on those which originate from its private portfolio. The fund increases its investment in portfolio companies by participating in a follow-on financing or after the portfolio company's IPO. It may acquire majority participations in portfolio companies, usually takes a seat on the portfolio company's Board of Directors, and largely makes equity investments but may also invest through other instruments including convertible bonds, debt securities, structured products, and derivatives. The fund exits its portfolio companies through trade sale or IPO.
Andreas Wicki
Bundesplatz 1, Zug
2014